The path ahead

The founding rationale for GALVmed was the substantial unrealised potential for translating global progress in research technologies into tangible livestock health products for the developing world. In bridging this gap, we use donor funding to de-risk product and commercial development costs that constrain the development of these much-needed products. This rationale remains equally valid today.

As a Product Development Partnership, we will continue to build our product development pipeline and will work on the development of 25 products and product-related technologies – processes or platforms that will increase access to products. We will maintain a global perspective on the livestock diseases affecting smallholder farmers and the potential for product development work to meet the needs of the smallholder sector. In addition to our 13 priority diseases,1 we will continue to consider the inclusion of additional diseases based on evidence of need and the potential for benefiting smallholders.

Our vision is that effective and affordable vaccines and medicines are made widely available and used by smallholders in the developing world. For this to happen, our initiatives need to achieve substantial levels of sales and market support that signify viable levels of market activity. These are the ‘tipping points’, after which GALVmed and www.galvmed.org 27 The path ahead donor funding is no longer required and where continued growth and expansion will come from market momentum. Our activities will be focused on the substantial scale up necessary to reach these tipping points. Achieving the desired level of scale will require a partnership approach with relevant organisations and a series of structured, market-based initiatives taking place.

The policy and regulatory environment can promote or hinder the sustainability and scalability of our activities. The objective of our policy work is to continue supporting the specific needs of product and commercial development activities. Although there is a broad spectrum of potential policy constraints from product development to ‘last mile’ delivery at the household level, we will focus on those areas that specifically affect project delivery.

For the next five years, we have committed to developing seven new high-impact livestock vaccines ready for commercial production and suitable for widespread use by smallholder farmers. We will also establish five large-scale product distribution networks in Africa and Asia and support other partners in establishing sustainable animal health delivery systems. We will continue to work on the Brucellosis Vaccine Prize initiative and the Tryps programme. The organisation and management of GALVmed, and the way our projects are designed, has been informed by the key learnings from the past decade. In particular, there will be:

Effective products can have a major impact on the lives of smallholder farmers. Few agricultural inputs can deliver the benefits that vaccines and veterinary medicines can. We remain committed to continuing success as we move into the next decade. It has been, and continues to be, a great privilege to contribute to protecting livestock and improving human lives.

1 African swine fever, porcine cysticercosis, AAT, brucellosis, RVF, haemorrhagic septicaemia, ECF, CBPP, CCPP, SGP, PPR, fowlpox and ND.

Insight

Five years after a ND vaccine market pilot project ended, a survey of one pilot area in Jhapa District, Nepal, and two pilot areas in Odisha State, India, showed that village retailers were still stocking the vaccine, vaccinators were delivering it, and smallholders were benefiting, with higher income from their poultry, driving sustainable demand.

Impact five years later